Checkpoint Therapeutics, Inc. (CKPT)
NASDAQ: CKPT · Real-Time Price · USD
4.040
0.00 (0.00%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Checkpoint Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Checkpoint Therapeutics stock have an average target of 4.33, with a low estimate of 4.10 and a high estimate of 4.80. The average target predicts an increase of 7.18% from the current stock price of 4.04.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Checkpoint Therapeutics stock from 3 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $4.8 | Strong Buy | Maintains | $4.8 | +18.81% | Mar 31, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $4.1 | Strong Buy → Hold | Downgrades | $4.1 | +1.49% | Mar 11, 2025 |
| Lake Street | Lake Street | Strong Buy → Hold Downgrades $7 → $4.1 | Strong Buy → Hold | Downgrades | $7 → $4.1 | +1.49% | Mar 10, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $9 → $4.8 | Strong Buy | Maintains | $9 → $4.8 | +18.81% | Mar 10, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Initiates $9 | Strong Buy | Initiates | $9 | +122.77% | Jan 13, 2025 |
Financial Forecast
Revenue This Year
41.94M
from 41.00K
Increased by 102,182.93%
Revenue Next Year
189.43M
from 41.94M
Increased by 351.71%
EPS This Year
-0.18
from -1.42
EPS Next Year
1.15
from -0.18
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 76.5M | 195.0M | 960.7M | ||
| Avg | 41.9M | 189.4M | 933.2M | ||
| Low | 9.2M | 182.0M | 896.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 186,409.8% | 365.0% | 407.1% | ||
| Avg | 102,182.9% | 351.7% | 392.6% | ||
| Low | 22,368.3% | 334.0% | 373.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.45 | 1.19 | 6.49 | ||
| Avg | -0.18 | 1.15 | 6.30 | ||
| Low | -0.76 | 1.11 | 6.06 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 463.0% | ||
| Avg | - | - | 446.9% | ||
| Low | - | - | 425.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.